Management guidelines for mucopolysaccharidosis VI

Roberto Giugliani, Paul Harmatz, James E. Wraith

    Research output: Contribution to journalArticlepeer-review


    Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) is a lysosomal storage disease that is characterized by systemic clinical manifestations and significant functional impairment. Diagnosis and management are often challenging because of the considerable variability in symptom presentation and rate of progression. The optimal standard of care should be based on evidence from randomized, controlled trials, meta-analyses, systematic reviews, and expert opinion. In support of this goal, comprehensive management guidelines have been drafted by an international group of experts in the management of patients with mucopolysaccharidosis VI. The guidelines provide a detailed outline of disease manifestations by body system, recommendations for regular assessments, and an overview of current treatment options. Copyright © 2007 by the American Academy of Pediatrics.
    Original languageEnglish
    Pages (from-to)405-418
    Number of pages13
    Issue number2
    Publication statusPublished - Aug 2007


    • Arylsulfatase B
    • Galsulfase
    • Hematopoietic stem cell transplantation
    • Lysosomal storage disease
    • Maroteaux-Lamy syndrome
    • Mucopolysaccharidosis
    • N-acetylgalactosamine-4-sulfatase


    Dive into the research topics of 'Management guidelines for mucopolysaccharidosis VI'. Together they form a unique fingerprint.

    Cite this